Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.


  ONCOgenic GPCR Network of Excellence and Training







General description

arGEN-X is a publically traded therapeutic antibody biotechnology company. We have a proprietary SIMPLE AntibodyTM discovery platform that allows us to discover high affinity, high diversity antibody sets covering essentially all epitopes of a given target. arGEN-X combines active immunisation of llamas with Fab phage display to induce and harvest conventional antibody output of the immune response. In addition to the antibody discovery platform arGEN-X has three Fc modulation technologies: PK enhancement through NHance; Abdeg technology for driving autoimmune antibodies into destruction and finally arGEN-X has a licence for the PotelligentTM technology which can significantly enhance antibody dependent cytotoxicity and tumour cell killing activity.


Key research facilities, infrastructures and equipment

760m2 lab space, equipped with two BiaCore 3000 instruments, FACS machine, AKTA Purifier Llama immunisations are performed off-site under supervision of arGEN-X employees or consultants.


Project members  

- Dr. Hans de Haard 

- Drs. Michael Saunders 

Contact details

Please contact us at:

ONCORNET Coordinator
VU University Amsterdam
The Netherlands

Funded by

marie curie actions   Marie Curie Actions



EU Horizon 2020



european union logo   European Union